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1. Introduction
The circulating levels of uric acid (UA) are higher and more
variable in humans and primates than in any other animals,
suggesting that the ability to maintain a high concentration of UA
results from a powerful natural selection process associated with
some important biological advantage.
Since UA has strong antioxidant properties (Hediger et al., 2005;
Reyes, 2005), a number of investigators have suggested that the
reason for selection is that circulating UA strongly and positively
affects human resistance to oxidative stress (Nieto et al., 2000;
Skalska et al., 2005; Reyes, 2005; Waring et al., 2006). In fact, once
differential concentrations are accounted for, the antioxidant power
of UA is substantially higher than other nonenzymatic antioxidants
such as ascorbic acid,a-andg-tocopherol,b-carotene, andprobably
also of enzymatic antioxidants such as superoxide dismutase and
catalase (Hediger et al., 2005). Interestingly, UA is also produced in
the vascular endothelium (Reyes, 2005) and there is evidence that in
its antioxidant activity, UA interacts with ascorbic acid (Sevanian
et al., 1991).
In spite of the strong theoretical rationale and the evidence
frompre-clinical studies, both suggesting a strong positive effect of
UA on human health, a number of epidemiological and clinical
studies (Jankowska et al., 2007; Shankar et al., 2007; Perlstein et al.,
2006; Bos et al., 2006; Sundstrom et al., 2005; Fang and Alderman,
2000) have suggested that UA is an important risk factor for
cardiovascular diseases and cardiovascular mortality and has a
strong negative effect on the clinical evolution of hypertension and
chronic heart failure. Interestingly, while other studies failed to
confirm the independent, negative prospective relationship
between UA and cardiovascular morbidity and mortality (Forman
et al., 2007; Coutinho et al., 2007; Hozawa et al., 2006; Wheeler
et al., 2005; Hu et al., 2001; Moriarity et al., 2000; Culleton et al.,
1999), evidence that UA is a protective factor or a marker of good
Mechanisms of Ageing and Development 129 (2008) 522–527
A R T I C L E I N F O
Article history:
Received 7 February 2008
Accepted 19 April 2008
Available online 30 April 2008
Keywords:
Uric acid
Antioxidants
Sarcopenia
Muscle strength
Elderly
A B S T R A C T
Background: Previous studies have shown that oxidative protein damage is independently associated
with low grip strength and that dietary intake and circulating levels of antioxidant vitamins are positive
predictors of muscle strength among older persons. Since uric acid (UA), has strong antioxidant
properties, we tested the hypothesis that UA levels is cross-sectionaly associated with muscle strength
and protective against the decline of strength over the aging process.
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health status is limited to few studies on acute cerebral ischemia
(Chamorro et al., 2004) and the protective effect of UA on oxidative
stress generated during physical activity (Waring et al., 2003).
Several mechanisms may explain the hypothetical negative effect
of UA on health, including a direct stimulating effect of soluble
non-crystalline UA on inflammation, the impairment of endothe-
lial function and the development of pro-oxidant properties in
specific metabolic conditions (Maxwell and Bruinsma, 2001;
Alderman, 2002; Hediger et al., 2005).
Understanding whether high UA is detrimental to health or
is a protective reaction aimed at counteracting the excessive
production of free radicals is a difficult task because of the
multiple potential sources of confounding. However, this scient-
ific question is clinically relevant because results may reshape
attitudes concerning treatment, especially in older persons, who
represent an increasing portion of the population in western
countries.
Aging is, in fact, associated with a progressive loss of muscle
mass and strength (Morley et al., 2001; Nair, 2005) and previous
studies have shown that poor muscle strength is a predictor of
incident disability and long-termmortality in healthymiddle-aged
men (Rantanen et al., 1999, 2000) and of cause-specific and total
mortality among older disabled women (Rantanen et al., 2003).
A previous cross-sectional study, using data from the InCHIANTI
Study, has found that dietary intake and circulating levels of
antioxidant vitamins are positive predictors of muscle strength in
older persons, independent of multiple potential confounders
(Cesari et al., 2004). Further, a recent study (Howard et al., 2007),
using data from the Women’s Health and Aging Study (WHAS) I,
has shown that oxidative protein damage is independently
associated with low grip strength among older women, suggesting
that oxidative stress might contribute to the loss of muscle
strength andmass in older adults. Finally,Waring et al. (2003) have
shown that UA exerts a protective effect on the oxidative stress
generated during physical activity. Accordingly, we hypothesized
that the ‘‘antioxidant’’ UA would be a strong, positive correlate of
muscle strength, and we tested this hypothesis in longitudinal
perspective using data collected in a population-based sample of
older persons.
2. Subjects and methods
2.1. Study sample
The analysis presented in this study is based upon data from the ‘‘InCHIANTI’’
(Invecchiare in Chianti, Aging in the Chianti area) Study, a perspective cohort
investigation on factors affecting loss of mobility in late life (Ferrucci et al., 2000).
The Ethical Committee of the Italian National Institute of Research and Care of
Aging approved the study protocol and all participants signed an informed
consent to be included in the study. Using a multistage sampling method, 1453
home-dwelling subjects were enrolled in two small towns (Greve in Chianti and
Bagno a Ripoli) located in the Chianti countryside. A detailed description of
sampling criteria used in the ‘‘InCHIANTI’’ Study is reported elsewhere (Ferrucci
et al., 2000).
Baseline data collection started in September 1998 and was completed in March
2000. Of the 1453 interviewed participants, 1156 were 65 years or older. Among
these, a UAmeasurewas available in 1058 participants, and performance, lower and
upper extremity strengthmeasures (see below)were available in 1016, 870 and 848
participants, respectively. Altogether, 789 participants (338 men, mean age
74.2  S.D. 6.4 years, and 451 women, mean age 75.4  S.D. 6.8 years) had complete
baseline data for the analysis presented in this paper.
During the 3-year follow-up, 46 of the 789 participants (27 men, mean age
80.5  S.D. 7.0 years, and 19 women, mean age 83.4  S.D. 7.0 years, 5.8% of the
sample) died: of these, 23 deaths (50%) were attributable to cardiovascular diseases, 14
(30%) to cancer and 9 (20%) to other causes.
Follow-up data collection started in October 2001 and was completed in March
2003. Of the 743 surviving participants with complete baseline data, performance,
lower and upper extremity strength measures (see below) were available in 608,
500 and 599 participants, respectively. Altogether, 497 participants (226 men,
mean age 75.6  S.D. 5.2 years, and 271 women, mean age 76.2  S.D. 5.5 years) also
had complete performance and strength measures at 3-year follow-up.
2.2. Uric acid
UA levels (mg/dL) were analyzed using enzymatic-colorimetric methods (Roche
Diagnostics, GmbH, Mannheim, Germany). The lower limits of detection were
0.2 mg/dL, range 0.2–25.0 mg/dL, CV intra-assay and inter-assay were equal 0.5%
and 1.7%, respectively.
Based upon the distribution of UA levels, participants were grouped according to
UA tertiles (<4.4 mg/dL, 4.4 and 5.5, and >5.5).
2.3. Other laboratory measures
Total cholesterol, HDL cholesterol, triglycerides and creatinine levels were
determined by commercial assays (Roche Diagnostics, Mannheim, Germany).
Insulin resistance was estimated by the homeostasis model assessment (HOMA-R
index) from the fasting glucose and insulin concentration according to the equation
HOMA-R index = [insulin (mU/mL)  glucose(mmol/L)]/22.5 (Matthews et al.,
1985). Plasma vitamin E (a- and g-tocopherol) concentrations were measured
by reversed-phase HPLC, as previously described by Martin (Cesari et al., 2004).
High sensitivity C-reactive protein (hs-CRP) was measured in duplicate using an
enzyme linked immunoadsorbent assay (ELISA) and colorimetric competitive
immunoassay that used purified protein and polyclonal anti-CRP antibodies. Serum
levels of interleukin 1 receptor antagonist (IL-1RA) and interleukin 6 (IL-6), were
measured by enzyme linked immunoadsorbent assay using ultrasensitive
commercial kits (Human Ultrasensitive, Biosource International Inc., Camarillo,
California USA).
2.4. Measures of physical function
Knee extension isometric strength was measured by a hand held dynamometer
applied at the calf level and multiplied for the length of the tibia, subtracted by
10 cm, in order to obtain the moment of the knee extension torque, in N dm, and to
make results comparable among participants with different heights (Lauretani
et al., 2003). Handgrip isometric strength, in kilograms, was used as a measure of
upper extremity muscle strength (Lauretani et al., 2003; Semba et al., 2007;
Dominguez et al., 2006; Abbatecola et al., 2005). We previously demonstrated that
the standardized protocol used in the InCHIANTI Study provides reliable measures
of strength (Bandinelli et al., 1999) and that knee extension torque and handgrip are
strongly correlated with strength of other muscle groups, respectively, of the lower
and upper extremities (Lauretani et al., 2003).
A lower extremity summary performance score (SPS) was derived from
performance in three objective tests: walking speed over 4 m, five timed repeated
chair rises, and standing balance. Each test was scored from 0 to 4 based upon
extensive normative data, and the three scores were summed to achieve a total
score, ranging from 0 to 12 (12 best) (Guralnik et al., 1994, 1995; Laukkanen et al.,
1995).
2.5. Other variables
Body mass index (BMI) was calculated from weight, in kilograms, and height, in
meters, according to the formula: W/(H)2. Physical activity was considered as an
ordinal variable and scored into five progressive grades: 0 = sedentary or light (<3
METS) physical activity<1 h/week; 1 = light physical activity 2–4 h/week; 2 = light
physical activity >4 h/week or moderate (3–6 METS) physical activity 1–2 h/week;
3 = moderate physical activity 3 h/week; 4 = intense (>6 METS) physical activity
several times a week (Ainsworth et al., 2000). Smoking was classed as ‘‘never’’,
‘‘current’’, or ‘‘former’’ if smoke cessation had lasted for at least 6months. Comorbid
conditions, such as diabetes, hypertension, stroke, peripheral artery disease,
coronary artery disease and chronic heart failure, were ascertained according to
pre-established algorithms that combined information gathered from medical
history, medical records, clinical examination, and blood and instrumental tests
included in the InCHIANTI Study protocol (Ferrucci et al., 2000). Assessment of
current dietary intakewas performed using the Italian version of the food frequency
questionnaire developed and validated in the context of the European Prospective
Investigation into Cancer and Nutrition (EPIC) (Pisani et al., 1997). The EPIC food
frequency questionnaire includes colored photographs to identify the portion size
usually consumed and provides a detailed assessment of food consumption.
Information on dietary intakewas transformed by special software into daily intake
of energy, macro- and micro-nutrients. Macro-nutrients known to affect UA levels,
such as total protein and alcohol, and micro-nutrients known to exert antioxidant
effects, such as vitamin C, vitamin E,b-carotene and retinol, were also considered as
potential confounders in this study.
2.6. Statistical analysis
Data are reported as mean  S.D. or as percentages. Statistical analysis was
performed using the STATA 7.0 software, from Stata Corporation (Texas, USA) and
carried out following a two-step strategy. The association of baseline UA with
participants’ characteristics, as well as with measures of physical function both at
baseline and at 3-year follow-up, was first tested independent of the confounding
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effect of age and sex, using linear or logistic regression models, as appropriate. The
association of baseline UA with measures of physical function was also tested by
further adjusting for BMI because large size people tend to have more muscle to
counteract gravity and move their larger body. Then, physical function measures that
showed a significant association with baseline UA were entered, as dependent
variables, into linear regression models in which UA was considered as the
independent variable and variables previously shown to be associated with UA as
covariates. In the models predicting physical measures at follow-up, analogous
baseline physical function measures were included among the independent variables
in order to obtain autoregressive models (Rosner et al., 1985). The initial fully adjusted
modelswere reduced to ‘‘most parsimonious’’models by using backward selection that
only retained variables independently associated with physical measures, with a p-
value <0.05. Continuous variables showing a markedly skewed distribution, such as
plasma antioxidants, inflammatory markers and vitamins dietary intake, were log-
transformed before being entered into calculations.
3. Results
Table 1 shows associations of baseline UA tertiles with
participants’ characteristics. Independent of the confounding
effect of age and sex, BMI, a diagnosis of hypertension and chronic
heart failure, plasma levels of triglycerides, HOMA-R index, serum
creatinine, a- and g-tocopherol, hs-C-reactive protein, IL-1RA and
IL-6, vitamin C dietary intake, number of medications and use of
diuretics were significantly higher across UA tertiles. On the
contrary, HDL cholesterol levels were significantly lower. Physical
activity in the past year, cigarette smoking, a diagnosis of diabetes,
peripheral and coronary artery disease, stroke, total cholesterol
levels, and dietary intake of vitamin E,b-carotene and retinol, were
not associated with UA.
Table 2 shows associations of baseline UA tertiles with
measures of muscle strength and physical performance, both at
baseline and at 3-year follow-up. Independent of the confounding
effect of age and sex, both handgrip and knee extension torque at
3-year follow-up significantly increased across UA tertiles and the
association remained significant after further adjusting for BMI.
The association of UA with handgrip and knee extension torque at
baseline was not significant, though both showed a clear-cut
increasing trend across UA tertiles. SPS was not associatedwith UA
both at baseline and at 3-year follow-up.
Table 3 shows the general linear autoregressive model testing
the relationship between baseline UA tertiles and follow-up
handgrip, reduced to a ‘‘most parsimonious’’ model by using back-
ward selection. After adjusting for baseline handgrip and other
relevant confounders, higher baseline UA levels were associated
with higher follow-up handgrip.
Table 4 shows the general linear autoregressive model testing
the relationship between baseline UA tertiles and follow-up knee
extension torque, reduced to a ‘‘most parsimonious’’ model
by using backward selection. After adjusting for baseline knee
Table 1
Baseline characteristics of InCHIANTI Study participants according to Uric acid tertiles (n. 789)a
Uric acid tertiles (mg/dL)
<4.4 4.4–5.5 >5.5 pb
Body mass index (kg/m2) (mean  S.D.) 26.0  3.7 27.7  4.1 28.3  3.9 <0.001
Physical activity (scale 0–4, 4 best) (mean  S.D.) 1.2  0.8 1.3  0.9 1.3  0.9 0.587
Cigarette smoking
Never smoked (%) 68.7 57.7 53.0
Former smokers (%) 19.3 30.9 35.7 0.621
Current smokers (%) 12.0 11.4 11.2
Comorbid conditions
Diabetes (%) 12.0 7.5 12.9 0.995
Hypertension (%) 65.2 72.6 77.9 0.001
Stroke (%) 3.9 5.5 8.0 0.126
Peripheral artery disease (%) 13.7 18.1 20.2 0.253
Coronary artery disease (%) 6.0 6.2 6.2 0.962
Chronic heart failure (%) 2.1 2.6 7.2 0.004
Lab tests
Total cholesterol (mg/dL) (mean  S.D. 220  38 220  37 218  41 0.075
HDL cholesterol (mg/dL) (mean  S.D.) 61  13 57  15 51  15 <0.001
Triglycerides (mg/dL) (mean  S.D.) 109  51 120  60 153  91 <0.001
Serum creatinine (mg/dL) (mean  S.D.) 0.8  0.1 0.9  0.2 1.0  0.3 <0.001
HOMA-R index (mean  S.D.) 2.7  1.8 2.5  1.4 3.2  2.3 <0.001
a-Tocopherol (mmol/L) (mean  S.D)c 29  7 30  8 31  10 <0.001
g-Tocopherol (mmol/L) (mean  S.D.)c 1.4  0.6 1.4  0.6 1.6  0.8 <0.001
C-reactive protein (mg/dL) (mean  S.D.)c 4.3  7.6 4.3  7.2 6.5  12.3 <0.001
Interleukin 1 receptor antagonist (pg/mL) (mean  S.D.)c 136  78 150  92 180  117 <0.001
Interleukin 6 (pg/mL) (mean  S.D.)c 1.8  2.1 1.9  1.9 2.4  2.6 0.004
Dietary intake (per day)
Total proteins (g) (mean  S.D.) 74.2  19.3 77.3  21.3 76.4  25.8 0.451
Alcohol (g) (mean  S.D.) 10.8  14.5 15.8  23.7 18.4  22.0 0.256
Vitamin C (mg) (mean  S.D.)c 106  544 113  49 117  53 0.005
Vitamin E (mg) (mean  S.D.)c 6.03  1.84 6.40  2.11 6.46  1.98 0.058
b-Carotene (mg) (mean  S.D.)c 2160  1160 2218  1167 2173  1065 0.514
Retinol (mg) (mean  S.D.)c 430  446 545  590 484  600 0.082
Drugs
No. of medications (mean  S.D.) 2.0  1.9 2.1  1.9 2.5  2.1 0.001
Allopurinol (%) 0.9 1.3 0.8 0.875
Diuretics (%) 5.6 8.1 16.9 <0.001
a According to uric acid tertiles, mean age was 74.4 years  S.D. 6.7 (n. 233, 77% women), 74.8  6.5 (n. 307, 54% women) and 75.4  6.8 (n. 249, 43% women), respectively.
b From age- and sex-adjusted linear or logistic regression models, as appropriate.
c Variables log-transformed before being entered into linear regressions due to their markedly skewed distribution.
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extension torque and other relevant confounders, higher baseline
UA levels were associated with higher follow-up knee extension
torque.
4. Discussion
Using data collected in a population-based sample of persons
enrolled in the ‘‘InCHIANTI’’ Study we tested the hypothesis that
the ‘‘antioxidant’’ UA could be a positive predictor of physical
performance and muscle strength in older persons and we found
that higher UA levels were prospectively independently associated
with better muscle strength.
To our knowledge, this is the first study that has investigated
the longitudinal relationship of UA with muscle strength and
physical performance. Therefore, our findings cannot be compared
with any existing literature.
Sarcopenia, the age-related loss of muscle mass and strength, is
considered one of the most important components in the causal
pathway leading to frailty, disabilityand, eventually, todeathamong
older persons (Evans, 1995; Fried and Guralnik, 1997; Rantanen
et al., 1999, 2000, 2003). A recent study (Howard et al., 2007) has
shown that oxidative protein damage is independently associated
with low grip strength among older persons, suggesting that oxi-
dative stress might contribute to the loss of muscle strength and
mass. Thus, our findings, showing an independent prospective
association of higher UA levels with bettermuscle function, support
the hypothesis that the ability tomaintain a higher concentration of
UA is associated with some important biological advantage, which
may consist in increased resistance to the excessive oxidative stress
that occurs in working muscles during everyday physical activity.
Interestingly, UA levels were not prospectively associated with
physical performance. This unexpected finding may be explained
by the fact that SPS is the final sum of a number of multiple
parameters, the result of which is affected not only by muscle
strength but also by other critical functions, such as balance and
coordination.
With regard to cross-sectional data, previous studies performed
on the same population sample have found that dietary intake and
serum concentration of antioxidant vitamins are a positive
predictor of physical performance and muscle strength in older
persons (Cesari et al., 2004). However, our cross-sectional findings
did not confirm the association between the ‘‘antioxidant’’ UA and
physical measures, though baseline handgrip and knee extension
Table 2
Muscle strength and physical performance measures according to uric acid tertiles
Uric acid tertiles (mg/dL)
<4.4 4.4–5.5 >5.5 pa pb
Baseline data (n. 789)c
Muscle strength measures
Handgrip (kg) (mean  S.D.) 23.2  10.0 27.3  12.0 28.3  12.1 0.304 0.149
Knee extension torque (N dm) (mean  S.D.) 332  123 389  169 407  198 0.061 0.232
Lower extremity summary of performance score (mean  S.D.) 10.3  2.4 10.3  2.5 10.1  2.6 0.127 0.535
Baseline data of participants whose 3-year follow-up data were also available (n. 497)d
Muscle strength measures
Handgrip (kg) (mean  S.D.) 25.0  10.1 29.4  12.4 32.0  11.2 0.066 0.052
Knee extension torque (N dm) (mean  S.D.) 330  99 393  135 418  132 0.023 0.113
Lower extremity summary of performance score (mean  S.D.) 11.0  1.3 10.9  1,7 11.1  1.3 0.706 0.836
3-year follow-up data (n. 497)
Muscle strength measures
Handgrip (kg) (mean  S.D.) 25.1  8.0 29.2  11.4 31.1  10.7 0.036 0.034
Knee extension torque (N dm) (mean  S.D.) 330  99 395  141 418  132 0.001 0.032
Lower extremity summary of performance score (mean  S.D.) 9.3  3.0 9.1  3.4 9.7  3.1 0.583 0.172
a From age- and sex-adjusted linear regressions.
b From linear regressions also adjusted for BMI.
c According to uric acid tertiles, mean age was 74.4 years  S.D. 6.7 (n. 233, 77% women), 74.8  6.5 (n. 307, 54% women) and 75.4  6.8 (n. 249, 43% women), respectively.
d According to uric acid tertiles, mean age at baseline was 72.5 years  S.D. 5.4 (n. 153, 75% women), 73.2  5.7 (n. 196, 51% women) and 73.7  5.1 (n. 148, 39% women),
respectively.
Table 3
General linearmodel testing the relationship between baseline uric acid tertiles and
follow-up handgrip after adjusting for baseline handgrip and other relevant
confounders. The initial fully adjustedmodelwas reduced to a ‘‘most parsimonious’’
model by using backward selection (p < 0.05)
Final model: Obs = 497; F = 432; Prob > F < 0.001; adjusted R2 = 0.782
Follow-up handgrip (kg) b  S.E. (b) p
Age (years) 0.35  0.04 <0.001
Female sex 8.70  0.61 <0.001
Uric acid tertiles (trend) 0.70  0.29 0.016
- Uric acid 1st tertile (<4.4 mg/dL) (reference) – –
- Uric acid 2nd tertile (4.4–5.5 mg/dL) 1.08  0.53 0.047
- Uric acid 3rd tertile (>5.5 mg/dL) 1.41  0.58 0.015
Baseline handgrip (kg) 0.41  0.03 <0.001
The initial fully adjustedmodel included: age, sex, BMI, hypertension, chronic heart
failure, HDL cholesterol, triglycerides, creatinin, HOMA-R index, a- and g-
tocopherol, C-reactive protein, interleukin 1 receptor antagonist, interleukin 6,
vitamin C intake, number of medications, use of diuretics and baseline handgrip.
Table 4
General linearmodel testing the relationship between baseline uric acid tertiles and
follow-up knee extension torque after adjusting for baseline knee extension torque
and other relevant confounders. The initial fully adjusted model was reduced to a
‘‘most parsimonious’’ model by using backward selection (p < 0.05).
Final model: Obs = 497; F = 145; Prob > F < 0.001; adjusted R2 = 0.657
Follow-up knee extension torque (N dm) b  S.E. (b) p
Age (years) 2.97  0.71 <0.001
Female sex 82.40  9.72 <0.001
Uric acid tertile (trend) 9.86  4.62 0.040
- Uric acid 1st tertile (<4.4 mg/dL) (reference) – –
- Uric acid 2nd tertile (4.4–5.5 mg/dL) 18.35  9.01 0.048
- Uric acid 3rd tertile (>5.5 mg/dL) 20.48  9.75 0.041
Body mass index (kg/m2) 2.66  1.00 0.008
n8 of medications 5.99  1.96 0.002
Baseline knee extension torque (N dm) 0.39  0.03 <0.001
The initial fully adjustedmodel included: age, sex, BMI, hypertension, chronic heart
failure, HDL cholesterol, triglycerides, creatinin, HOMA-R index, a- and g-
tocopherol, C-reactive protein, interleukin 1 receptor antagonist, interleukin 6,
vitamin C intake, number of medications, use of diuretics and baseline knee
extension torque.
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torque showed a clear-cut increasing trend across UA tertiles. We
may hypothesize that our cross-sectional findings are due to the
fact that low muscle strength indicates poor health status which
may be associated with excessive oxidative stress and possible
reactive increment in UA. However, if the compensatory increment
in UA is effective, it may protect against future decline in muscle
strength.
Two main potential limitations of the study need to be consi-
dered. First, our analysis was based upon UA serum levels that only
partially reflect the real amount of UA stored in the peripheral
tissues. Secondly, perspective studies that use a single baseline
measurement to predict future events are subject to the regression
dilution bias (MacMahon et al., 1990; Law et al., 1994). This bias
results fromthedilutingeffectsof randomfluctuationsof risk factors
over time such that single measures of risk factors systematically
underestimate the association between risk factors and events
(Grundy et al., 1999) Accordingly, we might have underestimated
the real association of some risk factor with the loss of muscle mass
and strength in older persons.
In conclusion, our findings show that higher levels of ‘‘anti-
oxidant’’ UA are prospectively associated with better muscle
function suggesting that UAmight represent a protective reaction
aimed at counteracting the excessive production of free radicals
that cause protein damage and eventually contribute to the
decline of muscle mass and strength in older persons (Howard
et al., 2007). Measures available in our epidemiological study do
not allow to discriminate whether higher UA levels prevent the
loss of muscle fibers or preserve the function of the remaining
ones. However, there is large evidence that the origin of age-
associated sarcopenia is due to a combination of reduction in
musclemass and intrinsicmuscle contractility, and it is likely that
the same mechanisms that induce muscle metabolic dysregula-
tion (probably catabolic imbalance) cause the reduction in
myofibers intrinsic contractility and later lead to muscle apopto-
sis and true sarcopenia. Further, the decrease of muscle strength,
which is the overall result of both the reduction in muscle mass
and intrinsic contractility, is also the most important parameter
impacting functional status and quality of life.
Future studies are needed to clarify the mechanism by which
higher levels of ‘‘antioxidant’’ UA positively affect muscle function
and to better understand to which extent we should reshape our
attitude concerning treatment of patients with slightly elevated
UA levels.
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